louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03629873: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
Official title: A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Lymphoma, Large B-Cell, Diffuse
Mantle Cell Lymphoma
Peripheral T Cell Lymphoma
Double-hit Lymphoma
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2018-08-14
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC combining with auto-HSCT to treat aggressive lymphoma Subjects


Eligibility criteria: Inclusion Criteria:

1. Aggressive lymphoma subjects: diffuse large B cell lymphoma confirmed by immunohistochemistry, aaIPI≥2 or double-hit lymphoma, as first-line consolidation; diffuse large B cell lymphoma as second-line consolidation therapy; peripheral T-cell lymphoma except ALK-positive type, as first-line or second-line consolidation therapy; mantle cell lymphoma, as first-line or second-line consolidation therapy.
2. Adequate organ system function including:

   Creatinine clearance rate ≥ 80ml/min and creatinine \< 160μmol/L ALT/AST ≤ 2 upper limit of normal Total Bilirubin \< 2 upper limit of normal FEV1、FVC and DLCO ≥ 50% predictive value Left ventricular ejection fraction ≥ 50% No Symptomatic arrhythmia
3. Age 18-60 years, male and female
4. ECOG score 0-1
5. Number of neutrophil ≥ 1.5×10\^9/L, number of platelet ≥ 70×10\^9/L, concentration of hemoglobin ≥ 90g/L, number of CD34+ cells ≥ 2.0×10\^6/kg
6. Expected survival ≥ 12 weeks
7. Volunteered to participate in this study and signed informed consent

Exclusion Criteria:

1. Have evidence of CNS lymphoma
2. Relapse after autologous hematopoietic stem cell transplantation
3. Active hepatitis B or hepatitis C virus infection
4. Severe active infection
5. HIV-infected persons
6. Liver cirrhosis or hepatic fibrosis
7. QTc \> 500ms
8. Have mental disorder or unable to sign informed consent
9. History of drug abuse and intemperance
10. Women who are pregnant or lactating or have breeding intent
11. The investigators believe that any increase in the risk of the subject or interference with the results of the trial

Primary outcomes:
measure: Progression-free survival rate
timeFrame: 2 years after transplantation
Secondary outcomes:
measure: Overall survival
timeFrame: 2 years after transplantation
measure: Complete remission
timeFrame: 3 months after transplantation
measure: Time of hematopoietic reconstitution
timeFrame: 15 days, 1 month
measure: Non-relapse mortality
timeFrame: 2 years
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Hematological Department, People's Hospital of Jiangsu Province
state: Jiangsu
Study officials:
References:
Clinical trial NCT03326973: Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
Official title: Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metastatic Melanoma
Keywords: Quality of Life (QoL)
17-518
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2017-10-31
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The melanoma service has agreed to provide this research team with access to a list of patients who are potentially eligible for this survey.

Brief summary: To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.


Eligibility criteria: Inclusion Criteria:

* Be able to speak and read English
* Be able to provide informed consent
* Have been diagnosed with metastatic melanoma at age 18 years or older
* Have been treated with either single agent or combination checkpoint inhibitor
* Be at least 12 months since first dose of above named agents
* Received no other systemic therapy after initiation of immunotherapy (interval radiation or surgery will be permitted based on review with primary treating medical oncologist)

Exclusion Criteria:

* Patients with cognitive, visual, or motor impairment such that they cannot complete the survey as assessed by the research or clinical team
* Patients who developed a subsequent cancer after starting on checkpoint inhibitor(s), exclusive of non-melanoma superficial skin cancers
* Patients with clinical documentation of progressive disease on the most recent assessment in the electronic medical record
* Patients with symptomatic progression but continue on immunotherapy

  * Note: For any patients where the disease status is not clear, we will confirm that the disease is either stable or responsive with their primary treating medical oncologist

Primary outcomes:
measure: total score of Global QOL overall health index
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memoral Sloan Kettering Basking Ridge
state: New Jersey
city: Middletown
country: United States
facility: Memoral Sloan Kettering Monmouth
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Commack
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Rockville Centre
country: United States
facility: Memorial Sloan Kettering Rockville Centre
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Deborah Korenstein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05555173: IVs With Buzzy in Chronic Pain Patients
Official title: IVs With Buzzy in Chronic Pain Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Chronic Pain
Acute Pain
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.
Sponsor class: OTHER
First posted: 2022-09-26
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The investigators are conducting a study to compare the effectiveness of the Buzzy® device with that of no pain relief method for IV placement in adults with chronic pain receiving lidocaine infusions.

Detailed description: IV placement is necessary for lidocaine infusions. Unfortunately, some patients say that placing an IV is painful. The investigators are conducting this study to evaluate two techniques that could make the placement of the IV more comfortable. Currently, some medical providers administer the IV without any pain-relieving techniques. Some medical providers place a device called Buzzy® on a patient's arm prior to the IV placement. The Buzzy® device is the combination of an ice pack and a vibrator in the shape of a bumble bee. Literature shows that the Buzzy® device makes IV placement more comfortable for children, but there is minimal data in regard to whether it is helpful for adult patients. The investigators are conducting this study to compare the effectiveness of the Buzzy® device with that of no pain relief method for IV placement in adults with chronic pain receiving lidocaine infusions. The use of the Buzzy® device in adults is the investigational part of the study. This device has been FDA approved for use.

Eligibility criteria: Inclusion Criteria:

* Patients receiving lidocaine infusions at the pain clinic.

Exclusion Criteria:

-

Primary outcomes:
measure: Pain on the Numeric Rating Scale
timeFrame: through study completion, an average of 2 months
Secondary outcomes:
measure: Satisfaction on the Visual Analog Scale
timeFrame: through study completion, an average of 2 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: St. Elizabeth's Medical Center
state: Massachusetts
Study officials:
affiliation: Pain Medicine Physician
name: Frederic Gerges, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06036173: Body Awareness and Functionality in Lymphedema
Official title: Effects of Lymphedema After Breast Cancer Treatment on Body Awareness and Upper Extremity Functionality
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphedema of Upper Limb
Lead sponsor: Selcuk University
Sponsor class: OTHER
First posted: 2023-09-13
Enrollment: 102
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: being a woman and having had breast cancer surgery

Brief summary: To determine whether body awareness and upper extremity functionality are affected in patients with or without lymphedema development after breast cancer surgery in comparison with individuals without a history of cancer.


Eligibility criteria: Inclusion Criteria:

first group:

* being female,
* being aged 18-65 years,
* having undergone unilateral breast cancer surgery,
* being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
* not having any orthopedic disease that would prevent walking, and volunteering to participate in the study.

second group:The inclusion criteria for the breast cancer surgery group

* without lymphedema were being female,
* being aged 18-65 years,
* having undergone unilateral breast cancer surgery, and volunteering to participate in the study.

Lastly, the inclusion criteria for the control group were:

* being female,
* being aged 18-65 years,
* having no history of cancer surgery, and volunteering to participate in the study.

Exclusion Criteria: for all groups

* not being willing to participate in the study;
* the presence of metastases, neurological, or orthopedic disorders;
* postural deformities, such as scoliosis and kyphosis;
* mental and cognitive disorders; or communication/cooperation problems

Primary outcomes:
measure: Body Awareness Questionnaire
timeFrame: 17 minutes
measure: Quick-Disabilities of the Arm, Shoulder, and Hand questionnaire
timeFrame: 11 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Selcuk University
state: Selcuklu
Study officials:
References:
Clinical trial NCT05858073: Investigation of Immediate Efficacy of Kinesiology Taping
Official title: Immediate Effects of Kinesiotaping on Pain, Proprioception, and Posture in Round Shoulder Individuals With Subacromial Impingement Syndrome: A Double-Blinded Randomized Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postural; Defect
Keywords: taping
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-05-15
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Shoulder protraction is the forward tilt of the head with hyperextension of the cervical spine and is associated with lengthening of the sternocleidomastoid and scalene muscles. With the lengthening of the flexor muscles, the weakened and shortened trapezius, levator scapula, and serratus anterior muscles lead to extra flexor torque and sustained contraction.

Detailed description: Weakness in the rotator cuff muscles, especially infraspinatus and supraspinatus muscles, has been observed in individuals with scapular dyskinesia and who frequently use overhead movements in their daily lives. The most important point to be considered in the treatment of scapular dyskinesia is the effective evaluation and treatment of primary and secondary symptoms and conditions. The preference of shoulder rehabilitation programs in which the scapula is also included in the treatment program will provide great benefits to physiotherapists in terms of treatment. Effective treatment can be provided by taping, exercise and many other treatment methods.

Eligibility criteria: Inclusion Criteria:

* Those with neck pain
* Being between 18-60 years old

Exclusion Criteria:

* Hypertension
* Cardiopulmonary disease
* Pregnancy
* malignancy
* Operation, injection, etc. for the neck in the last 3 months. those with a history of treatment
* Spine surgery
* Psychological discomfort
* Neurological and orthopedic deficits

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: one day
measure: New York Posture Scale
timeFrame: one day
measure: Proprioception Evaluation
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bahçehir University
Study officials:
References:
citation: Duperrat B, Puissant A, Larregue M, Fixy P. [Recklinghausen's neurofibromatosis with xanthoma]. Bull Soc Fr Dermatol Syphiligr. 1972;79(3):227. No abstract available. French.
Clinical trial NCT02236273: Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Official title: Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Human Papillomavirus
Keywords: Human papillomavirus
vaccination
text message
reminder
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: Agency for Healthcare Research and Quality (AHRQ)
First posted: 2014-09-10
Enrollment: 956
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored approach. The trans-theoretical model of behavior change supports tailoring interventions to an individual's stage of decision-making. Human papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is 90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV vaccine completion rates. Limited health literacy regarding the vaccine can affect series completion. The investigators will compare the effects of enhancing text message vaccination reminders with interactive, vaccine health literacy-promoting information tailored to vaccine decision making-stage on HPV vaccine series completion. The effects of these messages represent a new paradigm in interactive health communications.


Eligibility criteria: Inclusion Criteria:

* Parenting adult of adolescent age 11-17 years
* Adolescent received 1st dose of HPV at a study site within the last 2 weeks.
* Eligible parent's cell phone has text message capability

Exclusion Criteria:

* Language other than English or Spanish only
* Parent already in the study
* Intends to move away from the New York City area in \<12 months

Primary outcomes:
measure: HPV vaccine series completion
timeFrame: 12 months
Secondary outcomes:
measure: Time between 1st and 2nd dose
timeFrame: 2 months
measure: Time between 1st and 3rd dose
timeFrame: 6 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Melissa S Stockwell, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wynn CS, Catallozzi M, Kolff CA, Holleran S, Meyer D, Ramakrishnan R, Stockwell MS. Personalized Reminders for Immunization Using Short Messaging Systems to Improve Human Papillomavirus Vaccination Series Completion: Parallel-Group Randomized Trial. JMIR Mhealth Uhealth. 2021 Dec 27;9(12):e26356. doi: 10.2196/26356.
Clinical trial NCT02432573: Timing of Morning Rounds for Postpartum Hospitalized Women
Official title: Timing of Morning Rounds for Postpartum Hospitalized Women: A Randomized Controlled Quality Improvement Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physician Rounds
Postpartum
Keywords: timing
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2015-05-04
Enrollment: 150
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In postpartum hospitalized women, does delayed morning rounding improve patient satisfaction?

Detailed description: OBJECTIVE To investigate the timing of physician rounds on patient satisfaction

STUDY DESIGN Randomized, controlled, quality improvement trial

OUTCOMES Primary: score on Hospital Consumer Assessment of Healthcare Provers and Systems (HCAPS) survey

Secondary: score on Edinburgh Postnatal Depression Scale

Eligibility criteria: Inclusion Criteria:

* Delivered between 0600 and 0000
* Admitted to Memorial Hermann postpartum unit
* Patient managed by the University of Texas Physicians Group and/or obstetrics-gynecology residents

Exclusion Criteria:

- None

Primary outcomes:
measure: score on Hospital Consumer Assessment of Healthcare Provers and Systems (HCAPS) survey
timeFrame: 2 months
Secondary outcomes:
measure: score on Edinburgh Postnatal Depression Scale
timeFrame: 2 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: Texas Medical Center, Memorial Hermann Hospital
state: Texas
Study officials:
affiliation: University of Texas
name: Robyn P Roberts, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roberts RP, Blackwell SC, Brown KM, Pedroza C, Sibai BM, Tyson JE. Early Compared With Delayed Physician Rounds on Patient Satisfaction of Postpartum Women: A Randomized Controlled Trial. Obstet Gynecol. 2016 Aug;128(2):381-386. doi: 10.1097/AOG.0000000000001528.
Clinical trial NCT01399073: Virtual Reality for Neglect Diagnostics
Official title: Virtual Reality for Neglect Diagnostics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spatial Neglect
Stroke
Keywords: stroke
neglect
hemianopsia
virtual reality
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Median Klinik Kladow
name: Freie Universität Berlin
name: Berlin Center for Advanced Neuroimaging
name: Humboldt-Universität zu Berlin
name: NeuroCure Clinical Research Center, Charite, Berlin
First posted: 2011-07-21
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with acute (\< 2 wks after stroke), subacute (2 wks- 3 months after stroke)or chronic (3- 24 months after stroke)stroke with neglect or hemianopsia.

Healthy, age-matched controls.

Brief summary: Compared to the classical "paper and pencil"-tests, testing patients in our virtual reality setup might have a higher sensitivity and specificity.


Eligibility criteria: Inclusion Criteria for neglect patients:

* age ≥18 and \<80 years
* first stroke
* neglect symptoms
* no hemianopsia symptoms
* consent given by the patient

Inclusion Criteria for hemianopsia patients:

* age ≥18 and \<80 years
* first stroke
* no neglect symptoms
* hemianopsia symptoms
* consent given by the patient

Inclusion Criteria for Controls:

* age ≥18 and \<80 years
* no neurological deficits
* informed consent

Exclusion Criteria (for all groups):

* language comprehension deficits
* motor deficits of the upper extremities
* cognitive impairments (MMSE \<20 or SKT \>15 or DEMTEC \>12)
* depression
* seizure disorders
* claustrophobia

Primary outcomes:
measure: Feasibility
timeFrame: within the first 2 years after stroke
Secondary outcomes:
measure: Sensitivity and Specificity
timeFrame: within the first 2 years after stroke
measure: mri (functional (resting state) and structural imaging
timeFrame: within the first 2 years after stroke
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité University Medicine
Study officials:
affiliation: Charite University (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)
name: Andreas Meisel, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ulm L, Wohlrapp D, Meinzer M, Steinicke R, Schatz A, Denzler P, Klehmet J, Dohle C, Niedeggen M, Meisel A, Winter Y. A circle-monitor for computerised assessment of visual neglect in peripersonal space. PLoS One. 2013 Dec 12;8(12):e82892. doi: 10.1371/journal.pone.0082892. eCollection 2013.